GemPharmatech (688046.SH) shareholder Qingdao National Pharmaceutical reduced its holdings by 888,200 shares, decreasing its stake to 5%.
Yaokang Biopharmaceuticals (688046.SH) announced that on September 24, 2024, the company's shareholder, Qingdao Guoyao Daichuang...
GemPharmatech (688046.SH) announced on September 24, 2024, that its shareholder Qingdao Guoyao DaChuang Investment Partnership Enterprise (Limited Partnership) (referred to as "Qingdao Guoyao") has reduced its shareholding in the company by 888,200 shares through block trading, accounting for 0.22% of the total share capital of the company. After this equity change, Qingdao Guoyao holds a reduced stake of 5% in the company.
Related Articles
GF Securities: Three driving factors - macro narrative, fundamentals, and market liquidity. Still long on gold in the long term.
Predicting market bets on "global market value first": Next year, Alphabet Inc. Class C (GOOGL.US) will challenge NVIDIA Corporation (NVDA.US) and Apple Inc. (AAPL.US) head-on with AI chips.
New Stock News | Chang Guang Chenxin's second listing on the Hong Kong Stock Exchange ranks third among global CIS companies.
GF Securities: Three driving factors - macro narrative, fundamentals, and market liquidity. Still long on gold in the long term.
Predicting market bets on "global market value first": Next year, Alphabet Inc. Class C (GOOGL.US) will challenge NVIDIA Corporation (NVDA.US) and Apple Inc. (AAPL.US) head-on with AI chips.
New Stock News | Chang Guang Chenxin's second listing on the Hong Kong Stock Exchange ranks third among global CIS companies.
